Clinical pilot study on the effect of manipulation quantitative on the acupuncture treatment of stroke related insomnia

注册号:

Registration number:

ITMCTR2200006630

最近更新日期:

Date of Last Refreshed on:

2022-09-20

注册时间:

Date of Registration:

2022-09-20

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺量学对卒中相关失眠患者作用的临床预试验

Public title:

Clinical pilot study on the effect of manipulation quantitative on the acupuncture treatment of stroke related insomnia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺量学对卒中相关失眠患者作用的临床预试验

Scientific title:

Clinical pilot study on the effect of manipulation quantitative on the acupuncture treatment of stroke related insomnia

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200063890 ; ChiMCTR2200006630

申请注册联系人:

赵琦

研究负责人:

赵琦

Applicant:

Qi Zhao

Study leader:

Qi Zhao

申请注册联系人电话:

Applicant telephone:

13752195412

研究负责人电话:

Study leader's telephone:

13752195412

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

houhaowen2@163.com

研究负责人电子邮件:

Study leader's E-mail:

houhaowen2@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市西青区李七庄街昌凌路88号天津中医药大学第一附属医院

研究负责人通讯地址:

天津市西青区李七庄街昌凌路88号天津中医药大学第一附属医院

Applicant address:

NO88,Chang Ling road,Li qi zhuang street,Xi qing district,Tian jin city.China

Study leader's address:

NO88,Chang Ling road,Li qi zhuang street,Xi qing district,Tian jin city.China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津中医药大学第一附属医院

Applicant's institution:

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

TYLL2022[Z]字006

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

天津中医药大学第一附属医院医学伦理委员会

Name of the ethic committee:

IRB of The First Teaching Hospital of Tianjin University of TCM

伦理委员会批准日期:

Date of approved by ethic committee:

2022/6/30 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津中医药大学第一附属医院

Primary sponsor:

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

天津市西青区李七庄街昌凌路88号天津中医药大学第一附属医院

Primary sponsor's address:

NO88,Chang Ling road,Li qi zhuang street,Xi qing district,Tian jin city.China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

Country:

CHINA

Province:

Tian Jin City

City:

单位(医院):

天津中医药大学第一附属医院

具体地址:

天津市西青区李七庄街昌凌路88号天津中医药大学第一附属医院

Institution
hospital:

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Address:

NO88,Chang Ling road,Li qi zhuang street,Xi qing district,Tian jin city.China

经费或物资来源:

自筹

Source(s) of funding:

Self raised funds

研究疾病:

卒中相关失眠

研究疾病代码:

Target disease:

Stroke related insomnia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1、继续探索百会、四神聪深纳久留针对于卒中相关失眠患者的临床疗效; 并围绕针刺手法量学进行分析,优化针刺治疗方案; 2、应用主观量表与客观仪器评价,对卒中相关失眠患者的睡眠结构及针刺 方案疗效全面分析,提高卒中相关失眠的临床治疗水平; 3、根据本研究执行过程中及结果分析发现的问题,进一步完善课题方案。

Objectives of Study:

First, the further excavation of Baihui, Sishencong deep absorption and long-term needle retention method and the further analysis of acupuncture manipulation metrology are conducive to optimizing the acupuncture treatment strategy and improving the clinical treatment level of stroke related insomnia; Secondly, the application of subjective scales and objective instruments can help us to comprehensively analyze of the sleep structure of stroke related insomnia patients and the efficacy of acupuncture methods; Finally, we will improve the project plan according to the problems found in the implementation of this preliminary study and the analysis of the results, so as to carry out better research.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合脑梗死或脑出血诊断标准,并同时符合失眠症诊断标准者; (2)年龄 18~75 岁; (3)ISI 评分 8~21 分的轻中度失眠者; (4)能配合完成睡眠日记的患者; (5)能在治疗及随访期间保持既往固定助眠药物,并配合治疗师药物减停者; (6)患者或家属签署知情同意,配合治疗者。

Inclusion criteria

(1) Those who meet the diagnostic criteria of cerebral infarction or cerebral hemorrhage and insomnia at the same time; (2) Age 18~75 years old; (3) Mild to moderate insomnia with ISI score of 8-21; (4) Patients who can cooperate to complete the National Sleep Foundation Sleep Diary; (5) Those who can maintain the previous sleeping drugs during treatment and follow-up, and cooperate with the therapist to reduce the drug withdrawal; (6) Patients or family members sign informed consent and cooperate with treatment.

排除标准:

(1)无法沟通或有认知功能障碍的患者; (2)患有任何严重的不稳定的精神状况、严重的身体疾病及传染病; (3)正处于并将在半年内持续处于轮班工作的工作当中; (4)孕妇、哺乳期妇女、酗酒或酒精依赖者等; (5)头部外伤或选定穴位附近皮肤受损,研究者认为不宜接受针刺治疗者; (6)过去 1 个月内曾接受过针刺治疗失眠者; (7)正在参加其他临床研究者。

Exclusion criteria:

(1) Patients who are unable to communicate or have cognitive impairment; (2) Suffering from any serious unstable mental condition, serious physical disease and infectious disease; (3) Is in and will continue to work in shifts for half a year; (4) Pregnant women, lactating women, alcoholics or alcohol addicts, etc; (5) Head trauma or skin damage near the selected acupoints, which the researchers believe is not suitable for acupuncture treatment; (6) Those who have received acupuncture treatment for insomnia in the past month; (7) Participating in other clinical researchers.

研究实施时间:

Study execute time:

From 2022-09-20

To      2023-09-20

征募观察对象时间:

Recruiting time:

From 2022-09-20

To      2023-06-30

干预措施:

Interventions:

组别:

对照B组

样本量:

30

Group:

Control group B

Sample size:

干预措施:

基础治疗

干预措施代码:

BT

Intervention:

Basic treatment

Intervention code:

组别:

试验组

样本量:

30

Group:

Observation group

Sample size:

干预措施:

基础治疗+深纳久留针法

干预措施代码:

DL

Intervention:

Basic treatment and deep needle depth and long-term retention of Baihui and Sishencong points

Intervention code:

组别:

对照A组

样本量:

30

Group:

Control group A

Sample size:

干预措施:

基础治疗+深纳短留针法

干预措施代码:

DS

Intervention:

Basic treatment and deep needle depth and short-term retention of Baihui and Sishencong points

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津市

市(区县):

Country:

CHINA

Province:

TIan Jin City

City:

单位(医院):

天津中医药大学第一附属医院

单位级别:

三级甲等医院

Institution/hospital:

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Class A tertiary hospital

测量指标:

Outcomes:

指标中文名:

失眠严重程度指数

指标类型:

次要指标

Outcome:

the Insomnia Severity Index(ISI)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量量表

指标类型:

次要指标

Outcome:

12-Item Short-Form Health Survey(SF-12)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国国立卫生研究院脑卒中量表

指标类型:

次要指标

Outcome:

National Institute of Health stroke scale(NIHSS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睡眠日记

指标类型:

次要指标

Outcome:

NSFSD

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

服药记录卡

指标类型:

次要指标

Outcome:

Medication Record Card(MRC)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数量表

指标类型:

主要指标

Outcome:

PSQI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

多导睡眠监测仪数据

指标类型:

次要指标

Outcome:

the data of polysomnography(PSG)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

大便

组织:

Sample Name:

Shit

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用 spss 软件随机法将患者随机分成三组。受试者将由外部统计人员以 1:1:1 的分配比,采用 spss 软件随机分为三组之一。随机序列生成将在招募受试者之前进行,研究人员将对治疗条件保持设盲。

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS software was used to randomly divide the patients into three groups. The subjects will be randomly divided into one of three groups by external statisticians with a distribution ratio of 1:1:1 using SPSS software. Random sequence generation will be carried out before the recruitment of subjects,and researc

盲法:

本预实验为单盲研究设计 (1)受试者:按照随机分配的结果分配至所对应的分组,并接受该分组对 应的治疗方案; (2)操作者:针刺医师知晓受试者的分组及对应的治疗方案; (3)评价者:由不知晓研究分组的评价者对患者进行评价和记录数据; (4)统计者:最后的统计分析由第三方盲法进行。

Blinding:

This pre experiment adopts a single blind research design (1) Subjects: the subjects will be assigned to the corresponding group according to the results of random allocation, and receive the treatment plan corresponding to the group; (2) Operator: the acupuncturist knows the grouping of subjects and the corresponding treatment plan; (3) Evaluator: evaluators who do not know the study group evaluate patients and record data; (4) Statistician: the final statistical analysis is carried out by the third-party blind method.

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

-

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

-

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究将使用病例记录表来记录研究过程中产生的数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study will use the case record form to record the data generated during the study.

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above